image dons

I make a donation

ARCTIC

Evaluate the impact of the platelet function test VerifyNow with anti-aggregation individualisation treatment versus a conventional angioplasty strategy with active stent

Terminée

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

logo étude

objectif

High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization.

date de réalisation

2009

nombre de patients

2440

nombre de centres participants

38 french centers

type de financement

Public (APHP) and private (Fondation de France, Sanofi-Aventis, Cordis, Fondation SGAM, Abbott & Medtronic)

Référence

NCT00827411

Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy (ARCTIC)

Study Description

Our first hypothesis is that dose adjustment of aspirin and clopidogrel based on biological monitoring reduces the rate of severe cardiovascular complications compared to a conventional strategy in patients scheduled for drug eluting stent implantation and followed up for one year. Our second hypothesis is that interruption of clopidogrel / Prasugrel after one year of a combined therapy of clopidogrel/Prasugrel and aspirin is associated with a higher rate of severe cardiovascular complications as compared with patients in whom aspirin and clopidogrel / Prasugrel is maintained during the subsequent 6 months of follow-up.

source clinicaltrials.gov

Publications

  • Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy : Pharmacodynamic Insights From the ARCTIC Study
    Benoit Lattuca, Johanne Silvain, Yan Yan, Christophe Pouillot, Thomas Cuisset, Guillaume Cayla, Patrick Henry, Abdourahmane Diallo, Simon Elhadad, Grégoire Rangé, Thibault Lhermusier, Ziad Boueri, Pascal Motreff, Didier Carrié, Eric Vicaut, Gilles Montalescot, Jean-Philippe Collet
    Publicated in Circulation: Cardiovascular Interventions
  • Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration : Results of ARCTIC-Generation
    Jean-Philippe Collet, Johanne Silvain, Mathieu Kerneis, Thomas Cuisset, Nicolas Meneveau, Ziad Boueri, Olivier Barthélémy, Grégoire Rangé, Guillaume Cayla, Eric Van Belle, Simon Elhadad, Didier Carrié, Christophe Caussin, Hélène Rousseau, Pierre Aubry, Jacques Monségu, Pierre Sabouret, Stephen A O'Connor, Jérémie Abtan, Christophe Saint-Etienne, Farzin Beygui, Eric Vicaut, Gilles Montalescot, ARCTIC Investigators
    Publicated in Clinical Cardiology
  • Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention : the ARCTIC-GENE study
    Jean-Philippe Collet, Jean-Sébastien Hulot, Thomas Cuisset, Grégoire Rangé, Guillaume Cayla, Eric Van Belle, Simon Elhadad, Hélène Rousseau, Pierre Sabouret, Stephen A O'Connor, Jérémie Abtan, Mathieu Kerneis, Christophe Saint-Etienne, Olivier Barthélémy, Farzin Beygui, Johanne Silvain, Eric Vicaut, Gilles Montalescot, ARCTIC investigators
    Publicated in European Journal of Clinical Pharmacology
  • Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption) : a randomised trial
    Jean-Philippe Collet, Johanne Silvain, Olivier Barthélémy, Grégoire Rangé, Guillaume Cayla, Eric Van Belle, Thomas Cuisset, Simon Elhadad, François Schiele, Nicolas Lhoest, Patrick Ohlmann, Didier Carrié, Hélène Rousseau, Pierre Aubry, Jacques Monségu, Pierre Sabouret, Stephen A O'Connor, Jérémie Abtan, Mathieu Kerneis, Christophe Saint-Etienne, Farzin Beygui, Eric Vicaut, Gilles Montalescot, ARCTIC investigators
    Publicated in The Lancet
  • High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization : A landmark analysis of the ARCTIC study
    Gilles Montalescot, Grégoire Rangé, Johanne Silvain, Jean-Louis Bonnet, Ziad Boueri, Olivier Barthélémy, Guillaume Cayla, Loic Belle, Eric Van Belle, Thomas Cuisset, Simon Elhadad, Christophe Pouillot, Patrick Henry, Pascal Motreff, Didier Carrié, Hélène Rousseau, Pierre Aubry, Jacques Monségu, Pierre Sabouret, Stephen A O'Connor, Jérémie Abtan, Mathieu Kerneis, Christophe Saint-Etienne, Farzin Beygui, Eric Vicaut, Jean-Philippe Collet, ARCTIC Investigators
    Publicated in Circulation
  • Bedside monitoring to adjust antiplatelet therapy for coronary stenting
    Jean-Philippe Collet, Thomas Cuisset, Grégoire Rangé, Guillaume Cayla, Simon Elhadad, Christophe Pouillot, Patrick Henry, Pascal Motreff, Didier Carrié, Ziad Boueri, Loic Belle, Eric Van Belle, Hélène Rousseau, Pierre Aubry, Jacques Monségu, Pierre Sabouret, Stephen A O'Connor, Jérémie Abtan, Mathieu Kerneis, Christophe Saint-Etienne, Olivier Barthélémy, Farzin Beygui, Johanne Silvain, Eric Vicaut, Gilles Montalescot, ARCTIC Investigators
    Publicated in The New England Journal of Medecine
  • Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study
    Jean-Philippe Collet, Guillaume Cayla, Thomas Cuisset, Simon Elhadad, Grégoire Rangé, Eric Vicaut, Gilles Montalescot
    Publicated in American Heart Journal

Autres études

+

BIO-TAVI

En cours


Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI
+

AFIJI

En cours


Impact of genetics on occuring of coronary diseases in young patients and the pharmacogenetic of clopidogrel and its impact on the prognosis of patients having had angioplasty
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.